TITLE

ATL>The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A

AUTHOR(S)
Jacobs, R. Jake; Koff, Raymond S.; Meyerhoff, Allen S.
PUB. DATE
February 2002
SOURCE
American Journal of Gastroenterology;Feb2002, Vol. 97 Issue 2, p427
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES:Although hepatitis A vaccination is recommended for persons with chronic liver disease, the cost-effectiveness of vaccinating patients with chronic hepatitis C virus has not been extensively studied. We evaluated its costs and benefits.METHODS:A Markov model was used to assess cost-effectiveness from the health system and societal perspectives. Costs of hepatitis A screening and vaccination were compared with savings from reduced hepatitis A treatment and work loss to determine net costs of a “screen and vaccinate” strategy. Net costs were compared with longevity gains to assess cost-effectiveness.RESULTS:Based on hypothetical cohorts of 100,000 patients, vaccination would reduce the number of hepatitis A cases 63–72%, depending on patient age. Screening and vaccination costs of $5.2 million would be partially offset by $1.5–$2.8 million reductions in hepatitis A treatment costs and $0.2–$1.0 million reductions in work loss costs. From the health system perspective, vaccination would cost $22,256, $50,391, and $102,064 per life-year saved for patients vaccinated at ages 30, 45, and 60 yr, respectively. Cost-effectiveness ratios improve when work loss prevention is considered. Results are most sensitive to hepatitis A infection and hospitalization rates, and the rate used to discount future benefits to their present values.CONCLUSIONS:Hepatitis A vaccination of chronic hepatitis C patients would substantially reduce morbidity and mortality in all age groups examined. Consistent with other medical interventions for chronic hepatitis C patients, cost-effectiveness is most favorable for younger patients.
ACCESSION #
7755160

 

Related Articles

  • Chronic Hepatitis C in the United States. Deresinki, Stan // Clinical Infectious Diseases;10/15/2006, Vol. 43 Issue 8, pvi 

    The article presents the abstract of the paper "The Prevalence of Hepatitis C virus infection in the United States, 1999 Through 2002," by G.L. Armstrong and colleagues.

  • CORRECTION.  // Annals of Internal Medicine;9/6/2005, Vol. 143 Issue 5, p395 

    Presents a correction to an article on patient-to-patient transmission of hepatitis C virus, published previously in the periodical "Annals of Internal Medicine."

  • Hematologic Disorders Associated with Hepatitis C Virus Infection and Their Management. Dieterich, Douglas T.; Spivak, Jerry L. // Clinical Infectious Diseases;8/15/2003, Vol. 37 Issue 4, p533 

    More than 4 million people in the United States are infected with hepatitis C virus (HCV). During the next 20-30 years, the burden of HCV-related mortality and morbidity will likely double. To date, the most effective treatment for chronic HCV infection is the combination of either interferon...

  • Hepatitis C Virus Infection: Immune Responsiveness and Interferon-a Treatment. Jirillo, E.; Pellegrino, N.M.; Piazzolla, G.; Caccavo, D.; Antonaci, S. // Current Pharmaceutical Design;Jan2000, Vol. 6 Issue 2, p169 

    Hepatitis C virus (HCV) is responsible for most cases of posttransfusion hepatitis and sporadic or community-acquired non-A, non-B hepatitis. Different generations of enzyme-linked immunosorbent assay have been generated for detecting antibodies to HCV epitopes. HCV-RNA quantitative analysis has...

  • Biological and Clinical Significance of Endotoxemia in the Course of Hepatitis C Virus Infection. Caradonna, L.; Mastronardi, M.L.; Magrone, T.; Cozzolongo, R.; Cuppone, R.; Manghisi, O.G.; Caccavo, D.; Pellegrino, N.M.; Amoroso, A.; Jirillo, E.; L. Amati, E. // Current Pharmaceutical Design;May2002, Vol. 8 Issue 11, p995 

    Endotoxins or lipopolysaccharides (LPS), major components of the cell wall of Gram-negative bacteria, once released from the bacterial outer membrane bind to specific receptors and, in particular, to a membrane-bound receptor, the CD14 (mCD14) and the toll-like receptor 4 present on monocytes /...

  • Host Background Factors Contributing to Hepatitis C Virus Clearance. M.G. Isaguliants; N.N. Ozeretskovskaya // Current Pharmaceutical Biotechnology;Jun2003, Vol. 4 Issue 3, p185 

    This review is an attempt to characterize the host in the earliest events of hepatitis C virus (HCV) infection before the on-set of adaptive immune response. Host meets the replicating HCV with innate immune response in the form of proinflammatory cytokine production, activation of natural...

  • Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling. A. Lahm; A. Yagnik; A. Tramontano; U. Koch // Current Drug Targets;Aug2002, Vol. 3 Issue 4, p281 

    Hepatitis C virus (HCV), a member of the Flaviviridae family, has been recognised to be responsible for both parenterally transmitted and sporadic non-A and non-B hepatitis affecting 1-3% of the world population. HCV is a positive stranded RNA virus encoding a single polyprotein which contains...

  • Correction.  // New England Journal of Medicine;02/01/2001, Vol. 344 Issue 5, p392 

    A correction to the article "Patient-to-Patient Transmission of Hepatitis C Virus during Colonoscopy," that appeared in the July 24, 1997 issue, is presented.

  • What's the fuss about Hepatitis C? Pinette, Gilles // Windspeaker;May2002, Vol. 20 Issue 1, p21 

    Examines the epidemiology of hepatitis C virus. Symptoms and diagnosis; Treatment; Prevention.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics